Search results for "SEVERE ASTHMA"

showing 7 items of 57 documents

Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVID-19?

2021

severe asthma2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Severe asthmaImmunologyComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioCOVID-19 severe asthma COPDNOHumans; SARS-CoV-2; Asthma; COVID-19Internal medicineCorrespondencemedicineCOPDImmunology and AllergyHumansAsthmaCOVIDbusiness.industrySARS-CoV-2COVID-19asthmamedicine.diseaseItalybusiness
researchProduct

Real-world experience with dupilumab in severe asthma: One-year data from an italian named patient program

2021

Raffaele Campisi,1 Claudia Crimi,1 Santi Nolasco,2 Bianca Beghè,3 Leonardo Antonicelli,4 Gabriella Guarnieri,5 Nicola Scichilone,6 Morena Porto,2 Luigi Macchia,7 Giulia Scioscia,8 Maria Pia Foschino Barbaro,8 Alberto Papi,9 Nunzio Crimi1,2 1Respiratory Medicine Unit, A.O.U. Policlinico “G. Rodolico -San Marco”, Catania, Italy; 2Department of Clinical and Experimental Medicine, Section of Respiratory Diseases, University of Catania, Catania, Italy; 3Respiratory Medicine Unit, Department of Medicine, University of Modena and Reggio Emilia, Modena, Italy; 4Allergy Unit, Department of Internal Medicine, Ancona University Hospital, Ancona, Italy; 5Department of Car…

severe asthmaPulmonary and Respiratory MedicineSevere asthmareal-worldmedicine.medical_specialtyTreatment responseSevere asthmaSocio-culturaleDupilumab Named Patient Program Oral corticosteroids Real-world Severe asthmaHypereosinophiliaDupilumaboral corticosteroidsSettore MED/10 - Malattie Dell'Apparato Respiratoriolaw.inventionNamed Patient Program dupilumab oral corticosteroids real-world severe asthma03 medical and health sciences0302 clinical medicineRandomized controlled triallawdupilumabInternal medicineOral corticosteroidsJournal of Asthma and AllergymedicineImmunology and Allergy0601 history and archaeologyOriginal Research060102 archaeologybusiness.industryRetrospective cohort study06 humanities and the artsRC581-607Named Patient ProgramEosinophilDupilumabmedicine.anatomical_structureReal-world030228 respiratory systemCohortImmunologic diseases. Allergymedicine.symptombusinessDupilumab; Named Patient Program; Oral corticosteroids; Real-world; Severe asthma
researchProduct

Inquinamento ambientale, fumo e asma grave

2018

The health burden of air pollution on the world’s children is immense. Environmental factors are responsible for an estimated 26% of all children’s death worldwide. A large body of research exists on the effects of air pollution on children’s health, including effects on fetal growth, birth outcomes, lung development and function, asthma, respiratory infection and otitis media. It is also clearly linked to a higher risk of developing asthma, a major cause of morbidity in children. Indoor environments contribute significantly to total human exposure to air pollutants. Overall, people spend most time indoors. Pollutants remain in the air longer inside than outside. Some pollutants may be two …

severe asthmaindoor air pollutionrespiratory healthchildrenoutdoor air pollutionoutdoor air pollution indoor air pollution respiratory health children severe asthma
researchProduct

COVID-19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments

2020

To the Editor Since the end of February 2020 Italy, first non- Asian Country, has reported an ever increasing number of COronaVIrus Disease 19 (COVID-19) patients, which has reached over 200,000 confirmed Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) infected subjects and resulted in more than 34000 deaths (data updated to June 19th, 20201).Patients with asthma are potentially more severely affected by by SARS-CoV-2 infection 2 and it is well established that respiratory viral infections are associated with severe adverse outcomes in patients with asthma, including increased risk of asthma exacerbation episodes 3. Nonetheless, according to the epidemiological studies publishe…

severe asthmamedicine.medical_specialty2019-20 coronavirus outbreakCOVID-19 Severe Asthma Network in Italy inflammationCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Severe asthmaPopulationImmunologyMEDLINEOmalizumabSettore MED/10 - Malattie Dell'Apparato RespiratorioNOInternal medicineDiabetes mellitusSeverity of illnessmedicineImmunology and AllergyRisk factorLetters to the EditoreducationLetter to the EditorAsthmaeducation.field_of_studybusiness.industryIncidence (epidemiology)Mortality rateCOVID-19medicine.diseaseComorbiditySevere Asthma Network in ItalyinflammationCohortbusinessMepolizumabmedicine.drug
researchProduct

Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma

2021

BACKGROUND: Various studies have assessed omalizumab outcomes in the clinical practice setting but follow-up and/or number of patients included were limited. We aim to describe the long-term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real-life cohort reported to date. METHODS: ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients < 18 years and initiating omalizumab between 2006 and 2018, from the year prior to omalizumab initiation to discontinuation or last available follow-up. The primary outcome was the evolution of…

severe asthmamedicine.medical_specialtyPediatricsImmunology*real lifeOmalizumabhumanized monoclonal antibodiesOmalizumab*adolescentsAntibodies Monoclonal HumanizedAnti-asthmatic Agent03 medical and health sciences0302 clinical medicinechildrenreal lifeInternal medicinemedicine*anti-asthmatic agents*childrenHumansImmunology and AllergyChildren adolescents anti-asthmatic agents humanized monoclonal antibodies observational study omalizumab real-life severe asthmaAnti-Asthmatic Agentsadolescents030212 general & internal medicineChildAdverse effectRetrospective Studiesbusiness.industryasthmatic agents*observational studyanti&#8208Retrospective cohort studyAsthmaDiscontinuation*omalizumabTreatment OutcomePulmonology030228 respiratory system*humanized monoclonal antibodies*severe asthmaSevere persistent allergic asthmaPediatrics Perinatology and Child HealthCohortomalizumabobservational studyObservational studybusinessmedicine.drugPediatric Allergy and Immunology
researchProduct

The hidden burden of severe asthma: from patient perspective to new opportunities for clinicians

2020

Severe asthma is an important topic in respiratory diseases, due to its high impact on morbidity and mortality as well as on health-care resources. The many challenges that still exist in the management of the most difficult-to-treat forms of the disease, and the acknowledgement of the existence of unexplored areas in the pathophysiological mechanisms and the therapeutic targets represent an opportunity to gather experts in the field with the immediate goals to summarize current understanding about the natural history of severe asthma and to identify gaps in knowledge and research opportunities, with the aim to contribute to improved medical care and health outcomes. This article is a conse…

severe asthmamedicine.medical_specialtySevere asthmaprecision medicineAcknowledgementlcsh:MedicineSocio-culturaleReviewDiseasebiomarkers patient’s perspective precision medicine severe asthma.Medical care03 medical and health sciencesTherapeutic approach0302 clinical medicineMedicine030212 general & internal medicineddc:610Intensive care medicinebusiness.industrylcsh:RPerspective (graphical)General MedicineResearch opportunitiesBiomarkers patient’s perspective precision medicine severe asthmaBiomarkers; Patient’s perspective; Precision medicine; Severe asthmapatient’s perspectiveNatural history030228 respiratory systembusinessBiomarkers
researchProduct

A questionnaire to measure the extra-pulmonary symptoms of asthma

2021

Background: Research into the effects of asthma treatments on the extra-pulmonary symptoms of severe asthma is limited by the absence of a suitable questionnaire. The aim was to create a questionnaire suitable for intervention studies by selecting symptoms that are statistically associated with asthma pathology and therefore may improve when pathology is reduced. Methods: Patients attending a specialist asthma clinic completed the 65-item General Symptom Questionnaire (GSQ-65), a questionnaire validated for assessing symptoms of people with functional disorders. Lung function (FEV1%) and cumulative oral corticosteroids (OCS) calculated from maintenance dose plus exacerbations were obtained …

severe asthmamedicine.medical_specialtybusiness.industryEmergency medicinemedicineMeasure (physics)Extra pulmonarybusinessmedicine.diseaseextrapulmonary impactAsthma
researchProduct